Elena Poser
banner
eleposer.bsky.social
Elena Poser
@eleposer.bsky.social
Molecular Cell Biologist - Principal Scientist. Interests: RNA therapeutics, pharmacology, drug discovery, cell cycle research.
Very insightful synthesis of ideas and lessons on how human genetics is used to shape drug development @worksinprogress.bsky.social

worksinprogress.co/issue/nature...
Nature’s laboratory - Works in Progress Magazine
Millions of years of evolution have given us genomes that are like giant datasets for drug development. Finally, we are learning how to study them.
worksinprogress.co
November 28, 2025 at 1:13 PM
Reposted by Elena Poser
Thrilled to share our new paper describing the development and characterization of CDK11 inhibitors for cancer therapy. We also establish a new system that I think represents a huge leap forward in our ability to understand drug toxicity in a living organism.
August 4, 2025 at 6:27 PM
Reposted by Elena Poser
Happy to share our latest work from the Barr lab is now published in @embojournal.org

👉 WIP1 mutations suppress DNA damage triggered bypass of the mitotic timer | EMBO Journal

#cellcycle
@oxfordbiochemistry.bsky.social

www.embopress.org/doi/full/10....
WIP1 mutations suppress DNA damage triggered bypass of the mitotic timer | The EMBO Journal
imageimageProlonged delays in mitosis and G2 DNA-damage stress both lead to cell-cycle arrest in G1. This work shows how these pathways normally lead to G1 arrest by different routes, and how cancer-a...
www.embopress.org
June 23, 2025 at 11:14 AM
New definition of leaving a mark.
May 25, 2025 at 5:44 PM
Lot of work to do, but thanks to investors, we hope to bring ASOs for RNA editing to the clinic. Let's do this! #RNAtherapeutics #RNAediting #biotech
AIRNA Raises Oversubscribed $155 Million Series B Financing to Fund Phase 1/2 Clinical Trial for Alpha-1 Antitrypsin Deficiency and Future Pipeline — Airna
Financing led by Venrock Healthcare Capital Partners with co-lead Forbion Growth, and participation from RTW Investments, Nextech Invest, and other new
airna.com
April 1, 2025 at 5:33 PM
RNA editing has a lot of potential yet to be uncovered. We'll find out how to use it to cure diseases.
News: AIRNA: Harnessing the Body’s RNA-Editing System for Therapeutic Applications - CRISPR Medicine
Boston- and Germany-based biotech startup AIRNA is pioneering a new approach to genetic medicine by harnessing the body's natural RNA-editing machinery. Building on more than a decade of research in A...
crisprmedicinenews.com
February 24, 2025 at 4:32 PM
Reposted by Elena Poser
Fabulous work from our colleagues in the Barr lab showing how the CPC binds the nucleosome!

www.biorxiv.org/content/10.1...
A pivot-tether model for nucleosome recognition by the chromosomal passenger complex
Spatial restriction of Aurora B to centromeres during prometaphase and metaphase enables it to phosphorylate proteins necessary for spindle assembly checkpoint signalling and biorientation of chromoso...
www.biorxiv.org
January 23, 2025 at 10:22 PM
This paper from the Barr lab @oxfordbiochemistry.bsky.social is 🔥. MDM2 levels fall during mitosis due to short protein half life. When cells spend too much time in mitosis, too much MDM2 degradation occurs. As a result, p53 stabilizes triggering G1 arrest.
www.nature.com/articles/s41...
MDM2 functions as a timer reporting the length of mitosis - Nature Cell Biology
Fulcher et al. show that MDM2 times mitosis through self-catalysed ubiquitination and proteasomal destruction, triggering G1 arrest following delays in mitosis associated with chromosome instability a...
www.nature.com
January 9, 2025 at 12:22 PM